Cargando…

Natural Products-Based Nanoformulations: A New Approach Targeting CSCs to Cancer Therapy

Cancer stem cells (CSCs) lead to the occurrence and progression of cancer due to their strong tumorigenic, self-renewal, and multidirectional differentiation abilities. Existing cancer treatment methods cannot effectively kill or inhibit CSCs but instead enrich them and produce stronger proliferatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Wenhao, Li, Yuchen, Wang, Jing, Zhao, Maoyuan, Chen, Nianzhi, Zheng, Qiao, Wan, Lina, Mou, Yu, Tang, Jianyuan, Wang, Zhilei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482958/
https://www.ncbi.nlm.nih.gov/pubmed/36134202
http://dx.doi.org/10.2147/IJN.S380697
_version_ 1784791566164951040
author Liao, Wenhao
Li, Yuchen
Wang, Jing
Zhao, Maoyuan
Chen, Nianzhi
Zheng, Qiao
Wan, Lina
Mou, Yu
Tang, Jianyuan
Wang, Zhilei
author_facet Liao, Wenhao
Li, Yuchen
Wang, Jing
Zhao, Maoyuan
Chen, Nianzhi
Zheng, Qiao
Wan, Lina
Mou, Yu
Tang, Jianyuan
Wang, Zhilei
author_sort Liao, Wenhao
collection PubMed
description Cancer stem cells (CSCs) lead to the occurrence and progression of cancer due to their strong tumorigenic, self-renewal, and multidirectional differentiation abilities. Existing cancer treatment methods cannot effectively kill or inhibit CSCs but instead enrich them and produce stronger proliferation, invasion, and metastasis capabilities, resulting in cancer recurrence and treatment resistance, which has become a difficult problem in clinical treatment. Therefore, targeting CSCs may be the most promising approach for comprehensive cancer therapy in the future. A variety of natural products (NP) have significant antitumor effects and have been identified to target and inhibit CSCs. However, pharmacokinetic defects and off-target effects have greatly hindered their clinical translation. NP-based nanoformulations (NPNs) have tremendous potential to overcome the disadvantages of NP against CSCs through site-specific delivery and by improving their pharmacokinetic parameters. In this review, we summarize the recent progress of NPNs targeting CSCs in cancer therapy, looking forward to transforming preclinical research results into clinical applications and bringing new prospects for cancer treatment.
format Online
Article
Text
id pubmed-9482958
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-94829582022-09-20 Natural Products-Based Nanoformulations: A New Approach Targeting CSCs to Cancer Therapy Liao, Wenhao Li, Yuchen Wang, Jing Zhao, Maoyuan Chen, Nianzhi Zheng, Qiao Wan, Lina Mou, Yu Tang, Jianyuan Wang, Zhilei Int J Nanomedicine Review Cancer stem cells (CSCs) lead to the occurrence and progression of cancer due to their strong tumorigenic, self-renewal, and multidirectional differentiation abilities. Existing cancer treatment methods cannot effectively kill or inhibit CSCs but instead enrich them and produce stronger proliferation, invasion, and metastasis capabilities, resulting in cancer recurrence and treatment resistance, which has become a difficult problem in clinical treatment. Therefore, targeting CSCs may be the most promising approach for comprehensive cancer therapy in the future. A variety of natural products (NP) have significant antitumor effects and have been identified to target and inhibit CSCs. However, pharmacokinetic defects and off-target effects have greatly hindered their clinical translation. NP-based nanoformulations (NPNs) have tremendous potential to overcome the disadvantages of NP against CSCs through site-specific delivery and by improving their pharmacokinetic parameters. In this review, we summarize the recent progress of NPNs targeting CSCs in cancer therapy, looking forward to transforming preclinical research results into clinical applications and bringing new prospects for cancer treatment. Dove 2022-09-14 /pmc/articles/PMC9482958/ /pubmed/36134202 http://dx.doi.org/10.2147/IJN.S380697 Text en © 2022 Liao et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Liao, Wenhao
Li, Yuchen
Wang, Jing
Zhao, Maoyuan
Chen, Nianzhi
Zheng, Qiao
Wan, Lina
Mou, Yu
Tang, Jianyuan
Wang, Zhilei
Natural Products-Based Nanoformulations: A New Approach Targeting CSCs to Cancer Therapy
title Natural Products-Based Nanoformulations: A New Approach Targeting CSCs to Cancer Therapy
title_full Natural Products-Based Nanoformulations: A New Approach Targeting CSCs to Cancer Therapy
title_fullStr Natural Products-Based Nanoformulations: A New Approach Targeting CSCs to Cancer Therapy
title_full_unstemmed Natural Products-Based Nanoformulations: A New Approach Targeting CSCs to Cancer Therapy
title_short Natural Products-Based Nanoformulations: A New Approach Targeting CSCs to Cancer Therapy
title_sort natural products-based nanoformulations: a new approach targeting cscs to cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482958/
https://www.ncbi.nlm.nih.gov/pubmed/36134202
http://dx.doi.org/10.2147/IJN.S380697
work_keys_str_mv AT liaowenhao naturalproductsbasednanoformulationsanewapproachtargetingcscstocancertherapy
AT liyuchen naturalproductsbasednanoformulationsanewapproachtargetingcscstocancertherapy
AT wangjing naturalproductsbasednanoformulationsanewapproachtargetingcscstocancertherapy
AT zhaomaoyuan naturalproductsbasednanoformulationsanewapproachtargetingcscstocancertherapy
AT chennianzhi naturalproductsbasednanoformulationsanewapproachtargetingcscstocancertherapy
AT zhengqiao naturalproductsbasednanoformulationsanewapproachtargetingcscstocancertherapy
AT wanlina naturalproductsbasednanoformulationsanewapproachtargetingcscstocancertherapy
AT mouyu naturalproductsbasednanoformulationsanewapproachtargetingcscstocancertherapy
AT tangjianyuan naturalproductsbasednanoformulationsanewapproachtargetingcscstocancertherapy
AT wangzhilei naturalproductsbasednanoformulationsanewapproachtargetingcscstocancertherapy